Sprint Bioscience — Investor Relations & Filings

Sprint Bioscience is a pharmaceutical company specializing in the early-stage development of innovative drug candidates for oncology. The company utilizes a fragment-based drug discovery (FBDD) platform to efficiently identify and advance small-molecule therapies targeting difficult-to-treat cancers. Its business model is centered on out-licensing these drug programs to global pharmaceutical companies during the preclinical phase for further development and commercialization.